New combo aims to boost immune attack on tough melanoma
NCT ID NCT02816021
Summary
This study is testing whether adding an oral drug called azacitidine to the immunotherapy pembrolizumab can help control advanced melanoma. It is for patients who are new to this type of immunotherapy or whose cancer has worsened despite it. The main goal is to see if the combination shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77330, United States
Conditions
Explore the condition pages connected to this study.